Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
Loading...
Date
Authors
Ker, James A.
Journal Title
Journal ISSN
Volume Title
Publisher
Medpharm Publications
Abstract
The renin-angiotensin system (RAS) and angiotensin II, in
particular, play a central role and have been implicated in the
spectrum of cardiovascular disease (CVD), beginning with
hypertension, diabetes mellitus, atherosclerosis, myocardial
infarction (MI), strokes and heart failure.
Description
Keywords
Angiotensin-specific receptor blocker, Renin-angiotensin system (RAS), Cardiovascular disease (CVD), Angiotensin II, Hypertension, Diabetes mellitus, Heart failure, Aherosclerosis, Myocardial infarction (MI), Strokes, Angiotensin-converting enzyme inhibitor (ACE), Angiotensin-specific receptor blocker (ARB)
Sustainable Development Goals
Citation
Ker. JA 2015, 'Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?', South African Family Practice, vol. 57, no. 3, pp. 52-53.